Research Paper Volume 16, Issue 1 pp 246—266
The potential value of the Purinergic pathway in the prognostic assessment and clinical application of kidney renal clear cell carcinoma
- 1 Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China
Received: September 11, 2023 Accepted: November 16, 2023 Published: January 4, 2024
https://doi.org/10.18632/aging.205364How to Cite
Copyright: © 2024 Xie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The Purinergic pathway is involved in a variety of important physiological processes in living organisms, and previous studies have shown that aberrant expression of the Purinergic pathway may contribute to the development of a variety of cancers, including kidney renal clear cell carcinoma (KIRC). The aim of this study was to delve into the Purinergic pathway in KIRC and to investigate its potential significance in prognostic assessment and clinical treatment. 33 genes associated with the Purinergic pathway were selected for pan-cancer analysis. Cluster analysis, targeted drug sensitivity analysis and immune cell infiltration analysis were applied to explore the mechanism of Purinergic pathway in KIRC. Using the machine learning process, we found that combining the Lasso+survivalSVM algorithm worked well for predicting survival accuracy in KIRC. We used LASSO regression to pinpoint nine Purinergic genes closely linked to KIRC, using them to create a survival model for KIRC. ROC survival curve was analyzed, and this survival model could effectively predict the survival rate of KIRC patients in the next 5, 7 and 10 years. Further univariate and multivariate Cox regression analyses revealed that age, grading, staging, and risk scores of KIRC patients were significantly associated with their prognostic survival and were identified as independent risk factors for prognosis. The nomogram tool developed through this study can help physicians accurately assess patient prognosis and provide guidance for developing treatment plans. The results of this study may bring new ideas for optimizing the prognostic assessment and therapeutic approaches for KIRC patients.
Abbreviations
ACC: Adrenocortical Carcinoma; ADP: Adenosine Diphosphate; ATP: Adenosine Triphosphate; AUC: Area Under the Curve; BLCA: Bladder Urothelial Carcinoma; BRCA: Breast Invasive Carcinoma; CCR: Chemokine Receptor; CESC: Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma; CHOL: Cholangiocarcinoma; CNV: Copy Number Variation; COAD: Colon Adenocarcinoma; DLBC: Diffuse Large B-cell Lymphoma; DSS: Disease-Specific Survival; EMT: Epithelial-Mesenchymal Transition; ESCA: Esophageal Carcinoma; GBM: Glioblastoma Multiforme; GSCA: Gene Set Co-expression Analysis; GSEA: Gene Set Enrichment Analysis; HDAC: Histone Deacetylase; HNSC: Head and Neck Squamous Cell Carcinoma; HR: Hazard Ratio; IC50: Half Maximal Inhibitory Concentration; KICH: Kidney Chromophobe; KIRC: Kidney Renal Clear Cell Carcinoma; KIRP: Kidney Renal Papillary Cell Carcinoma; K-M: Kaplan-Meier; LAML: Acute Myeloid Leukemia; LASSO: Least Absolute Shrinkage and Selection Operator; LGG: Brain Lower Grade Glioma; LIHC: Liver Hepatocellular Carcinoma; LOOCV: Leave-One-Out Cross-Validation; LUAD: Lung Adenocarcinoma; LUSC: Lung Squamous Cell Carcinoma; MESO: Mesothelioma; OS: Overall Survival; OV: Ovarian Serous Cystadenocarcinoma; PAAD: Pancreatic Adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; PFI: Progression-Free Interval; PI3K: Phosphatidylinositol-3-Kinase; PRAD: Prostate Adenocarcinoma; RCC: Renal Cell Carcinoma; READ: Rectum Adenocarcinoma; SIRT: Sirtuin; SKCM: Skin Cutaneous Melanoma; SNV: Single Nucleotide Variation; STAD: Stomach Adenocarcinoma; STES: Stomach and Esophageal Carcinoma; TCGA: The Cancer Genome Atlas; TGCT: Testicular Germ Cell Tumors; THCA: Thyroid Carcinoma; THYM: Thymoma; UCEC: Uterine Corpus Endometrial Carcinoma; UCS: Uterine Carcinosarcoma; UVM: Uveal Melanoma; VEGF: Vascular Endothelial Growth Factor.